Analytical Data
-
Gene name
BCAR1
- Application
-
Alternative Names
CAS; CRKAS; P130Cas; CASS1; Crk-Associated Substrate; Cas Scaffolding Protein Family Member 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P56945
-
Expression Region
Met1~Leu240
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCAR1, or Breast Cancer Anti-Estrogen Resistance 1, is a gene originally identified for its role in conferring resistance to anti-estrogen therapies in breast cancer cells. The BCAR1 protein has been implicated in various signaling pathways that regulate cell growth, survival, and motility, particularly in the context of cancer progression and metastasis. Its function relates to the integration of cellular responses to extracellular signals, making it a crucial player in tumor biology. Researchers have focused on the biochemical properties of BCAR1, exploring its interactions with other proteins and signaling molecules, which provide insights into cell survival mechanisms in hormone-resistant breast cancer. BCAR1 has also been studied for its potential as a therapeutic target, as inhibiting its function may enhance the efficacy of existing breast cancer treatments. The study of BCAR1 recombinant protein is essential to elucidate its mechanism of action and validate its potential as a biomarker for resistant breast cancer. Understanding the structure and function of this protein could lead to novel therapeutic strategies aimed at overcoming treatment resistance, ultimately improving patient outcomes in breast cancer management.
